{"id":{"repo_id":"qu-belfast","oai_identifier":"oai:pure.qub.ac.uk/portal:studenttheses/f7d39c9c-b4b4-4e3a-987d-859731a2851e"},"canonical_url":"https://search.dev.ndltd.org/etd/qu-belfast/oai:pure.qub.ac.uk/portal:studenttheses/f7d39c9c-b4b4-4e3a-987d-859731a2851e","repository":{"repo_id":"qu-belfast","name":"Queen's University Belfast","base_url":"https://pureadmin.qub.ac.uk/ws/oai"},"display":{"title":"Clinical utility of 3D power doppler ultrasound and maternal biomarkers in the prediction of pre-eclampsia in high-risk pregnancies","abstract":"Globally, pre-eclampsia is a leading cause of maternal and fetal morbidity and mortality. Approximately 2% of all pregnant women develop pre-eclampsia; women with high-risk co-morbidities are particularly at risk with reported incidences of up to 20%. Evolving evidence suggests that an integrated screening tool combining medical history, ultrasound parameters and serum biomarkers may be of use in defining the patient-specific risk for pre-eclampsia.<br/><br/>Against this background, this thesis examines the ability of baseline maternal characteristics, placental vascularisation indices, uterine artery Doppler and maternal serum biomarkers (Pregnancy Associated Plasma Protein-A (PAPP-A), Placental like Growth Factor (PlGF), soluble Fms-like tyrosine kinase (sFLt-1) and soluble Endoglin (sEng)) measured in the first and second trimesters of pregnancy to predict pre-eclampsia in high-risk women.<br/><br/>To determine the added clinical utility and predictive value of these biophysical and biochemical parameters, a prospective longitudinal observational study of high-risk women and low-risk control participants was carried out (PREDICT). Set within the context of a systematic review evaluating the ability of (first trimester) placental vascularisation indices to predict pre-eclampsia, findings from the PREDICT study demonstrate that placental vascularisation indices perform well for prediction of pre-eclampsia in the first trimester and that measurements are repeatable and reproducible within a high-risk cohort. The added clinical utility of uterine artery Doppler ultrasound for prediction of pre-eclampsia in high-risk women was not apparent, however the additional clinical utility of a number of first (sFlt-1, sFlt-1:PlGF) and second trimester biomarkers (PlGF:sEng) was demonstrated. Results from the PREDICT study indicate a potential role for a first trimester combined screening model in high-risk women incorporating information about baseline maternal characteristics, vascularisation flow index and sFlt-1. In addition, an integrated screening model combining baseline maternal characteristics and flow index is proposed for prediction of pre-eclampsia in the second trimester.<br/><br/>Exploratory sub-group analysis demonstrated differences in performance of placental vascularisation indices, uterine artery Doppler and serum biomarkers in prediction of pre-eclampsia. In particular, this thesis highlights the increased prevalence of obesity in pregnancy and its subsequent impact on performance of placental vascularisation indices and maternal serum biomarkers.<br/><br/>Future research should focus on better understanding the underlying mechanisms for pre-eclampsia in different sub-groups. Additional research is needed to extend current understanding of pre-eclampsia risk in relation to Body Mass Index trajectory and to explore suitable biomarker threshold ranges for prediction of pre-eclampsia in obese cohorts.<br/><br/>Adoption of a combined screening model early in pregnancy to identify those women at highest risk of pre-eclampsia has the potential to significantly improve maternal and neonatal outcomes. It is evident that supplementary research to investigate the role of combined screening models for pre-eclampsia within high-risk sub-groups is required before introduction in a clinical setting. In challenging the existing pathways of antenatal care, clinicians have an opportunity to provide personalised medical care for women at greatest risk.","abstract_html":"Globally, pre-eclampsia is a leading cause of maternal and fetal morbidity and mortality. Approximately 2% of all pregnant women develop pre-eclampsia; women with high-risk co-morbidities are particularly at risk with reported incidences of up to 20%. Evolving evidence suggests that an integrated screening tool combining medical history, ultrasound parameters and serum biomarkers may be of use in defining the patient-specific risk for pre-eclampsia.&lt;br/&gt;&lt;br/&gt;Against this background, this thesis examines the ability of baseline maternal characteristics, placental vascularisation indices, uterine artery Doppler and maternal serum biomarkers (Pregnancy Associated Plasma Protein-A (PAPP-A), Placental like Growth Factor (PlGF), soluble Fms-like tyrosine kinase (sFLt-1) and soluble Endoglin (sEng)) measured in the first and second trimesters of pregnancy to predict pre-eclampsia in high-risk women.&lt;br/&gt;&lt;br/&gt;To determine the added clinical utility and predictive value of these biophysical and biochemical parameters, a prospective longitudinal observational study of high-risk women and low-risk control participants was carried out (PREDICT). Set within the context of a systematic review evaluating the ability of (first trimester) placental vascularisation indices to predict pre-eclampsia, findings from the PREDICT study demonstrate that placental vascularisation indices perform well for prediction of pre-eclampsia in the first trimester and that measurements are repeatable and reproducible within a high-risk cohort. The added clinical utility of uterine artery Doppler ultrasound for prediction of pre-eclampsia in high-risk women was not apparent, however the additional clinical utility of a number of first (sFlt-1, sFlt-1:PlGF) and second trimester biomarkers (PlGF:sEng) was demonstrated. Results from the PREDICT study indicate a potential role for a first trimester combined screening model in high-risk women incorporating information about baseline maternal characteristics, vascularisation flow index and sFlt-1. In addition, an integrated screening model combining baseline maternal characteristics and flow index is proposed for prediction of pre-eclampsia in the second trimester.&lt;br/&gt;&lt;br/&gt;Exploratory sub-group analysis demonstrated differences in performance of placental vascularisation indices, uterine artery Doppler and serum biomarkers in prediction of pre-eclampsia. In particular, this thesis highlights the increased prevalence of obesity in pregnancy and its subsequent impact on performance of placental vascularisation indices and maternal serum biomarkers.&lt;br/&gt;&lt;br/&gt;Future research should focus on better understanding the underlying mechanisms for pre-eclampsia in different sub-groups. Additional research is needed to extend current understanding of pre-eclampsia risk in relation to Body Mass Index trajectory and to explore suitable biomarker threshold ranges for prediction of pre-eclampsia in obese cohorts.&lt;br/&gt;&lt;br/&gt;Adoption of a combined screening model early in pregnancy to identify those women at highest risk of pre-eclampsia has the potential to significantly improve maternal and neonatal outcomes. It is evident that supplementary research to investigate the role of combined screening models for pre-eclampsia within high-risk sub-groups is required before introduction in a clinical setting. In challenging the existing pathways of antenatal care, clinicians have an opportunity to provide personalised medical care for women at greatest risk.","abstract_has_math":false,"creators":["Eastwood, Kelly-Ann"],"institution":"Queen's University Belfast","degree_name":"Doctor of Philosophy","degree_level":"Doctoral Thesis","degree_discipline":null,"degree_department":null,"school":null,"contributors":[],"advisors":["Young, Ian","Holmes, Valerie"],"committee_chairs":[],"committee_members":[],"year":2018,"date_issued":"2018-7","date_published":"2018-7","updated_at":"2026-07-24T03:55:45Z","subjects":[],"languages":["eng"],"rights":[],"rights_urls":[],"identifier_entries":[{"key":"dc:identifier","label":"Identifier","values":["oai:pure.qub.ac.uk/portal:studenttheses/f7d39c9c-b4b4-4e3a-987d-859731a2851e"],"render_values":[{"text":"oai:pure.qub.ac.uk/portal:studenttheses/f7d39c9c-b4b4-4e3a-987d-859731a2851e","href":null,"code":true}]}]},"links":{"outbound_url":"https://pure.qub.ac.uk/en/studentTheses/f7d39c9c-b4b4-4e3a-987d-859731a2851e","outbound_label":"Repository record","outbound_source":"dc:identifier"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.advisor","label":"Advisor","values":["Young, Ian","Holmes, Valerie"]},{"key":"dc:creator","label":"Author","values":["Eastwood, Kelly-Ann"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2018-7"]},{"key":"dc:date.issued","label":"Date","values":["2018-7"]},{"key":"dc:publisher.department","label":"Dc Publisher Department","values":["School of Medicine, Dentistry and Biomedical Sciences"]},{"key":"dc:publisher.institution","label":"Dc Publisher Institution","values":["Queen's University Belfast"]},{"key":"dc:relation.isreferencedby","label":"Dc Relation Isreferencedby","values":["https://pure.qub.ac.uk/en/studentTheses/f7d39c9c-b4b4-4e3a-987d-859731a2851e"]},{"key":"dc:type","label":"Dc Type","values":["Thesis"]},{"key":"dc:type.qualificationlevel","label":"Dc Type Qualificationlevel","values":["Doctoral Thesis"]},{"key":"dc:type.qualificationname","label":"Dc Type Qualificationname","values":["Doctor of Philosophy"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language","label":"Dc Language","values":["eng"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["oai:pure.qub.ac.uk/portal:studenttheses/f7d39c9c-b4b4-4e3a-987d-859731a2851e","https://pure.qub.ac.uk/en/studentTheses/f7d39c9c-b4b4-4e3a-987d-859731a2851e"]},{"key":"dc:identifier.uri","label":"Identifier URI","values":["https://pure.qub.ac.uk/files/230503775/Clinical_Utility_of_3D_Power_Doppler_Ultrasound_and_Maternal_Biomarkers_in_the_Prediction_of_Pre_eclampsia_in_High_risk_Pregnancies.pdf"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["Globally, pre-eclampsia is a leading cause of maternal and fetal morbidity and mortality. Approximately 2% of all pregnant women develop pre-eclampsia; women with high-risk co-morbidities are particularly at risk with reported incidences of up to 20%. Evolving evidence suggests that an integrated screening tool combining medical history, ultrasound parameters and serum biomarkers may be of use in defining the patient-specific risk for pre-eclampsia.<br/><br/>Against this background, this thesis examines the ability of baseline maternal characteristics, placental vascularisation indices, uterine artery Doppler and maternal serum biomarkers (Pregnancy Associated Plasma Protein-A (PAPP-A), Placental like Growth Factor (PlGF), soluble Fms-like tyrosine kinase (sFLt-1) and soluble Endoglin (sEng)) measured in the first and second trimesters of pregnancy to predict pre-eclampsia in high-risk women.<br/><br/>To determine the added clinical utility and predictive value of these biophysical and biochemical parameters, a prospective longitudinal observational study of high-risk women and low-risk control participants was carried out (PREDICT). Set within the context of a systematic review evaluating the ability of (first trimester) placental vascularisation indices to predict pre-eclampsia, findings from the PREDICT study demonstrate that placental vascularisation indices perform well for prediction of pre-eclampsia in the first trimester and that measurements are repeatable and reproducible within a high-risk cohort. The added clinical utility of uterine artery Doppler ultrasound for prediction of pre-eclampsia in high-risk women was not apparent, however the additional clinical utility of a number of first (sFlt-1, sFlt-1:PlGF) and second trimester biomarkers (PlGF:sEng) was demonstrated. Results from the PREDICT study indicate a potential role for a first trimester combined screening model in high-risk women incorporating information about baseline maternal characteristics, vascularisation flow index and sFlt-1. In addition, an integrated screening model combining baseline maternal characteristics and flow index is proposed for prediction of pre-eclampsia in the second trimester.<br/><br/>Exploratory sub-group analysis demonstrated differences in performance of placental vascularisation indices, uterine artery Doppler and serum biomarkers in prediction of pre-eclampsia. In particular, this thesis highlights the increased prevalence of obesity in pregnancy and its subsequent impact on performance of placental vascularisation indices and maternal serum biomarkers.<br/><br/>Future research should focus on better understanding the underlying mechanisms for pre-eclampsia in different sub-groups. Additional research is needed to extend current understanding of pre-eclampsia risk in relation to Body Mass Index trajectory and to explore suitable biomarker threshold ranges for prediction of pre-eclampsia in obese cohorts.<br/><br/>Adoption of a combined screening model early in pregnancy to identify those women at highest risk of pre-eclampsia has the potential to significantly improve maternal and neonatal outcomes. It is evident that supplementary research to investigate the role of combined screening models for pre-eclampsia within high-risk sub-groups is required before introduction in a clinical setting. In challenging the existing pathways of antenatal care, clinicians have an opportunity to provide personalised medical care for women at greatest risk."]},{"key":"dc:title","label":"Title","values":["Clinical utility of 3D power doppler ultrasound and maternal biomarkers in the prediction of pre-eclampsia in high-risk pregnancies"]}]}],"canonical_facts":{"dc:contributor.advisor":["Young, Ian","Holmes, Valerie"],"dc:creator":["Eastwood, Kelly-Ann"],"dc:date":["2018-7"],"dc:date.issued":["2018-7"],"dc:description.abstract":["Globally, pre-eclampsia is a leading cause of maternal and fetal morbidity and mortality. Approximately 2% of all pregnant women develop pre-eclampsia; women with high-risk co-morbidities are particularly at risk with reported incidences of up to 20%. Evolving evidence suggests that an integrated screening tool combining medical history, ultrasound parameters and serum biomarkers may be of use in defining the patient-specific risk for pre-eclampsia.<br/><br/>Against this background, this thesis examines the ability of baseline maternal characteristics, placental vascularisation indices, uterine artery Doppler and maternal serum biomarkers (Pregnancy Associated Plasma Protein-A (PAPP-A), Placental like Growth Factor (PlGF), soluble Fms-like tyrosine kinase (sFLt-1) and soluble Endoglin (sEng)) measured in the first and second trimesters of pregnancy to predict pre-eclampsia in high-risk women.<br/><br/>To determine the added clinical utility and predictive value of these biophysical and biochemical parameters, a prospective longitudinal observational study of high-risk women and low-risk control participants was carried out (PREDICT). Set within the context of a systematic review evaluating the ability of (first trimester) placental vascularisation indices to predict pre-eclampsia, findings from the PREDICT study demonstrate that placental vascularisation indices perform well for prediction of pre-eclampsia in the first trimester and that measurements are repeatable and reproducible within a high-risk cohort. The added clinical utility of uterine artery Doppler ultrasound for prediction of pre-eclampsia in high-risk women was not apparent, however the additional clinical utility of a number of first (sFlt-1, sFlt-1:PlGF) and second trimester biomarkers (PlGF:sEng) was demonstrated. Results from the PREDICT study indicate a potential role for a first trimester combined screening model in high-risk women incorporating information about baseline maternal characteristics, vascularisation flow index and sFlt-1. In addition, an integrated screening model combining baseline maternal characteristics and flow index is proposed for prediction of pre-eclampsia in the second trimester.<br/><br/>Exploratory sub-group analysis demonstrated differences in performance of placental vascularisation indices, uterine artery Doppler and serum biomarkers in prediction of pre-eclampsia. In particular, this thesis highlights the increased prevalence of obesity in pregnancy and its subsequent impact on performance of placental vascularisation indices and maternal serum biomarkers.<br/><br/>Future research should focus on better understanding the underlying mechanisms for pre-eclampsia in different sub-groups. Additional research is needed to extend current understanding of pre-eclampsia risk in relation to Body Mass Index trajectory and to explore suitable biomarker threshold ranges for prediction of pre-eclampsia in obese cohorts.<br/><br/>Adoption of a combined screening model early in pregnancy to identify those women at highest risk of pre-eclampsia has the potential to significantly improve maternal and neonatal outcomes. It is evident that supplementary research to investigate the role of combined screening models for pre-eclampsia within high-risk sub-groups is required before introduction in a clinical setting. In challenging the existing pathways of antenatal care, clinicians have an opportunity to provide personalised medical care for women at greatest risk."],"dc:identifier":["oai:pure.qub.ac.uk/portal:studenttheses/f7d39c9c-b4b4-4e3a-987d-859731a2851e","https://pure.qub.ac.uk/en/studentTheses/f7d39c9c-b4b4-4e3a-987d-859731a2851e"],"dc:identifier.uri":["https://pure.qub.ac.uk/files/230503775/Clinical_Utility_of_3D_Power_Doppler_Ultrasound_and_Maternal_Biomarkers_in_the_Prediction_of_Pre_eclampsia_in_High_risk_Pregnancies.pdf"],"dc:language":["eng"],"dc:publisher.department":["School of Medicine, Dentistry and Biomedical Sciences"],"dc:publisher.institution":["Queen's University Belfast"],"dc:relation.isreferencedby":["https://pure.qub.ac.uk/en/studentTheses/f7d39c9c-b4b4-4e3a-987d-859731a2851e"],"dc:title":["Clinical utility of 3D power doppler ultrasound and maternal biomarkers in the prediction of pre-eclampsia in high-risk pregnancies"],"dc:type":["Thesis"],"dc:type.qualificationlevel":["Doctoral Thesis"],"dc:type.qualificationname":["Doctor of Philosophy"]},"updated_at":"2026-07-24T03:55:45Z"}